AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17430436 — intervention group
Group type: COMPARATOR
Intervention: Conventional workstations
Number of subjects: 97
Study 15773400 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliomyelitis vaccine (IPV) 'Imovax Polio'
Number of subjects: 0
Study 15773400 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vaccine (following IPV)
Number of subjects: 0
Study 12200465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal erythroblast numbers and cell-free DNA concentrations in maternal blood samples
Number of subjects: 0
Study 12200465 — intervention group
Group type: COMPARATOR
Intervention: Pathological placental conditions
Number of subjects: 0
Study 10417577 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox injections to the glabella, forehead or lateral canthal regions
Number of subjects: 40
Study 10417577 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (control group)
Number of subjects: 40
Study 7732714 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle changes program (low-fat vegetarian diet, stress management techniques, aerobic exercises, group support meetings)
Number of subjects: 40
Study 7732714 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 20 mg/day (lipid-lowering drug)
Number of subjects: 40
Study 2277377 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole (1 g intramuscularly preoperatively)
Number of subjects: 81
Study 2277377 — intervention group
Group type: COMPARATOR
Intervention: Cefonicid (1 g intramuscularly preoperatively)
Number of subjects: 81
Study 6153260 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster immune globulin (ZIG)
Number of subjects: 97
Study 6153260 — intervention group
Group type: COMPARATOR
Intervention: Normal serum globulin (NSG)
Number of subjects: 97
Study 31905354 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleleader
Number of subjects: 22
Study 31905354 — intervention group
Group type: COMPARATOR
Intervention: Teleconsultant
Number of subjects: 22
Study 31729982 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib + bendamustine/rituximab
Number of subjects: 416
Study 31729982 — intervention group
Group type: COMPARATOR
Intervention: Placebo + bendamustine/rituximab
Number of subjects: 416
Study 28249075 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (diagnostic labels provided)
Number of subjects: 20
Study 28249075 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (no information)
Number of subjects: 20
Study 28249075 — intervention group
Group type: EXPERIMENTAL
Intervention: ADSD severity
Number of subjects: 20
Study 28249075 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional information about ADSD
Number of subjects: 20
Study 26226029 — intervention group
Group type: EXPERIMENTAL
Intervention: PHAX
Number of subjects: 24
Study 26226029 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 24
Study 24167992 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound
Number of subjects: 224
Study 24167992 — intervention group
Group type: COMPARATOR
Intervention: Low-temperature plasm radiofrequency
Number of subjects: 224
Study 20393478 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐NCPAP
Number of subjects: 18
Study 20393478 — intervention group
Group type: COMPARATOR
Intervention: V‐NCPAP
Number of subjects: 18
Study 19589241 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 60
Study 19589241 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg/day)
Number of subjects: 60
Study 17557045 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux (GER)
Number of subjects: 0
Study 17557045 — intervention group
Group type: COMPARATOR
Intervention: Empirical treatment for extraesophageal manifestations of GER
Number of subjects: 0
Study 14994324 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam oral solution
Number of subjects: 108
Study 14994324 — intervention group
Group type: COMPARATOR
Intervention: Lormetazepam tablets
Number of subjects: 108
Study 11488780 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 18
Study 11488780 — intervention group
Group type: COMPARATOR
Intervention: Control (no omeprazole)
Number of subjects: 18
Study 10197085 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH therapy (0.125U/kg/wk increasing to 0.25U/kg/wk)
Number of subjects: 30
Study 10197085 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH therapy
Number of subjects: 30
Study 10197085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7908246 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (12 micrograms)
Number of subjects: 15
Study 7908246 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salbutamol (200 micrograms)
Number of subjects: 15
Study 7908246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 4042528 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg nicotine base in a 30% aqueous solution
Number of subjects: 10
Study 4042528 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo solution
Number of subjects: 10
Study 30883188 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional loading after a 12-week healing period
Number of subjects: 32
Study 30883188 — intervention group
Group type: COMPARATOR
Intervention: Immediate loading within one week after insertion
Number of subjects: 32
Study 28965648 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release oxycodone with supportive strategies
Number of subjects: 122
Study 28965648 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release oxycodone
Number of subjects: 122
Study 27052743 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous CIK cell immunotherapy in combination with chemotherapy (FOLFOX4 plan)
Number of subjects: 122
Study 27052743 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (FOLFOX4 plan) alone
Number of subjects: 122
Study 25461784 — intervention group
Group type: EXPERIMENTAL
Intervention: Technician-administered internet cognitive behaviour therapy (iCBT)
Number of subjects: 67
Study 25461784 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 67
Study 22956251 — intervention group
Group type: EXPERIMENTAL
Intervention: VBLOC® Therapy (vagal blockade)
Number of subjects: 503
Study 22956251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vagal blockade)
Number of subjects: 503
Study 22956251 — intervention group
Group type: EXPERIMENTAL
Intervention: VBLOC® Therapy (vagal blockade) with ≥ 12 h/day use
Number of subjects: 503
Study 22956251 — intervention group
Group type: COMPARATOR
Intervention: Control group with ≥ 12 h/day use
Number of subjects: 503
Study 20202489 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxcinod 375 mg
Number of subjects: 918
Study 20202489 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxcinod 750 mg
Number of subjects: 918
Study 20202489 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg
Number of subjects: 918
Study 20202489 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 918
Study 17967821 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CPAP (CPAP alone for 15 min)
Number of subjects: 124
Study 17967821 — intervention group
Group type: EXPERIMENTAL
Intervention: Late CPAP (CPAP added to medical treatment for 15 min)
Number of subjects: 124
Study 17967821 — intervention group
Group type: EXPERIMENTAL
Intervention: Early CPAP
Number of subjects: 124
Study 17967821 — intervention group
Group type: COMPARATOR
Intervention: Late CPAP
Number of subjects: 124
Study 17283268 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery grafts
Number of subjects: 880
Study 17283268 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein grafts
Number of subjects: 880
Study 17283268 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 880
Study 14967728 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 100 mg
Number of subjects: 3717
Study 14967728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3717
Study 11035317 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 294
Study 11035317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 8638755 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard physical therapy program with patellar taping
Number of subjects: 25
Study 8638755 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy program without patellar taping
Number of subjects: 25
Study 1483075 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination group with nurse coordinators
Number of subjects: 554
Study 1483075 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 554
Study 4048835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat (50 g)
Number of subjects: 8
Study 4048835 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein (50 g)
Number of subjects: 8
Study 4048835 — intervention group
Group type: COMPARATOR
Intervention: Starch (50 g)
Number of subjects: 8
Study 31204114 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA‐IM (150 mg/mL every 3 months)
Number of subjects: 7830
Study 31204114 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper IUD
Number of subjects: 7830
Study 31204114 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG implant
Number of subjects: 7830
Study 31204114 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA‐IM
Number of subjects: 7830
Study 28683283 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlexanox
Number of subjects: 42
Study 26118815 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help program for parents of children with ADHD (1 year duration, 8 booklets, 14 telephone consultations up to 20 minutes each)
Number of subjects: 274
Study 26118815 — intervention group
Group type: COMPARATOR
Intervention: Guided self-help program for parents of children with ADHD
Number of subjects: 274
Study 23044388 — intervention group
Group type: EXPERIMENTAL
Intervention: NTP treated for 10s with sand-blasting (SB)
Number of subjects: 24
Study 23044388 — intervention group
Group type: EXPERIMENTAL
Intervention: NTP treated for 10s with Clearfil ceramic primer (MDP)
Number of subjects: 24
Study 23044388 — intervention group
Group type: EXPERIMENTAL
Intervention: NTP treated for 10s with sand-blasting+MDP (SBMDP)
Number of subjects: 24
Study 23044388 — intervention group
Group type: EXPERIMENTAL
Intervention: NTP treated for 10s with baseline (B)
Number of subjects: 24
Study 21545459 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-focused rumination
Number of subjects: 0
Study 21545459 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocation-focused rumination
Number of subjects: 0
Study 21545459 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of rumination
Number of subjects: 0
Study 19701647 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 11
Study 19701647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 17669768 — intervention group
Group type: EXPERIMENTAL
Intervention: Swine gelatin plus rifamycin
Number of subjects: 557
Study 17669768 — intervention group
Group type: COMPARATOR
Intervention: Bone wax
Number of subjects: 557
Study 15194131 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg as a single shot
Number of subjects: 741
Study 15194131 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 200 mg once daily for 3 days
Number of subjects: 741
Study 15194131 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg twice daily for 3 days
Number of subjects: 741
Study 11707763 — intervention group
Group type: EXPERIMENTAL
Intervention: Word-only descriptions of stool consistency classifications
Number of subjects: 103
Study 11707763 — intervention group
Group type: EXPERIMENTAL
Intervention: Word + diagram descriptions of stool consistency classifications
Number of subjects: 103
Study 11707763 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects' classifications on days 1 and 2
Number of subjects: 103
Study 11707763 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects' classifications compared with investigators
Number of subjects: 103
Study 9158269 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine hydrochloride
Number of subjects: 20
Study 9158269 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine hydrochloride
Number of subjects: 20
Study 8424511 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of morphine in 25 mL of saline (Group 1)
Number of subjects: 40
Study 8424511 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mL of 0.25% bupivacaine (62.5 mg) (Group 2)
Number of subjects: 40
Study 8424511 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5 mg of morphine and 62.5 mg of bupivacaine in 25 mL dilution (Group 3)
Number of subjects: 40
Study 8424511 — intervention group
Group type: COMPARATOR
Intervention: 25 mL of saline (Group 4)
Number of subjects: 40
Study 3318543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 4 micrograms/kg/minute
Number of subjects: 60
Study 3318543 — intervention group
Group type: COMPARATOR
Intervention: Morphine 33 micrograms/minute
Number of subjects: 60
Study 3318543 — intervention group
Group type: COMPARATOR
Intervention: Morphine infusion
Number of subjects: 60
Study 3318543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 60
Study 29161166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (motivational element, quitting preparation components, pre-quit nicotine patch)
Number of subjects: 222
Study 29161166 — intervention group
Group type: COMPARATOR
Intervention: Control group (attention control)
Number of subjects: 222
Study 29161166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 222
Study 27480840 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin with ACE inhibitor
Number of subjects: 3323
Study 27480840 — intervention group
Group type: COMPARATOR
Intervention: Placebo with ACE inhibitor
Number of subjects: 3323
Study 27480840 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin without ACE inhibitor
Number of subjects: 3323
Study 27480840 — intervention group
Group type: COMPARATOR
Intervention: Placebo without ACE inhibitor
Number of subjects: 3323
Study 27480840 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of ACE inhibitor
Number of subjects: 3323
Study 24864326 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual microincision cataract surgery (MICS)
Number of subjects: 50
Study 24864326 — intervention group
Group type: COMPARATOR
Intervention: 2.2-mm coaxial phacoemulsification
Number of subjects: 50
Study 21195430 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt (EPCS)
Number of subjects: 211
Study 21195430 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (EST)
Number of subjects: 211
Study 20045571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmologists classifying optic disc photographs
Number of subjects: 243
Study 20045571 — intervention group
Group type: COMPARATOR
Intervention: GDx‐VCC nerve fiber indicator
Number of subjects: 243
Study 20045571 — intervention group
Group type: COMPARATOR
Intervention: HRT's best classifier
Number of subjects: 243
Study 20045571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver agreement (kappa)
Number of subjects: 243
Study 18287833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold needle
Number of subjects: 80
Study 18287833 — intervention group
Group type: COMPARATOR
Intervention: Room temperature needle
Number of subjects: 80
Study 16158688 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-based intervention (15 weeks, 3 times a week, 30 minutes each session)
Number of subjects: 2
Study 16158688 — intervention group
Group type: COMPARATOR
Intervention: Direct instruction (15 weeks, 3 times a week, 30 minutes each session)
Number of subjects: 2
Study 11912360 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tranilast eye drops
Number of subjects: 52
Study 11912360 — intervention group
Group type: COMPARATOR
Intervention: Vehicle saline solution
Number of subjects: 52
Study 9707351 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-propranolol 80 mg
Number of subjects: 15
Study 9707351 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-propranolol 80 mg
Number of subjects: 15
Study 9707351 — intervention group
Group type: EXPERIMENTAL
Intervention: rac-propranolol 160 mg
Number of subjects: 15
Study 8520187 — intervention group
Group type: EXPERIMENTAL
Intervention: 200‐mg vaginal progesterone suppositories
Number of subjects: 17
Study 8520187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1669270 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy in A Group (10 patients)
Number of subjects: 21
Study 1669270 — intervention group
Group type: COMPARATOR
Intervention: Control group B (11 patients)
Number of subjects: 21
Study 308357 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (selective)
Number of subjects: 55
Study 308357 — intervention group
Group type: COMPARATOR
Intervention: Nonselective shunting procedures
Number of subjects: 55
Study 308357 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal flow (selective and nonselective)
Number of subjects: 55
Study 308357 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing portal perfusion
Number of subjects: 55
Study 31593588 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV gB/MF59 vaccine
Number of subjects: 15
Study 31409568 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation + lyso-thermosensitive liposomal doxorubicin (LTLD)
Number of subjects: 0
Study 31409568 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation only
Number of subjects: 0
Study 31409568 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups analyzed for BPV effect
Number of subjects: 0
Study 28131322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine extended release (D-ER) 10 mg BID
Number of subjects: 24
Study 28131322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25501294 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zopiclone
Number of subjects: 31
Study 23242595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance
Number of subjects: 459
Study 21333385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin infusion without nasogastric tube placement (erythromycin group)
Number of subjects: 253
Study 21333385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube placement without erythromycin (nasogastric group)
Number of subjects: 253
Study 21333385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin infusion combined with nasogastric tube placement (nasogastric-erythromycin group)
Number of subjects: 253
Study 21333385 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 253
Study 19892392 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment (Oportunidades programme for 18 months earlier)
Number of subjects: 1793
Study 19892392 — intervention group
Group type: COMPARATOR
Intervention: Late treatment (Oportunidades programme started 18 months later)
Number of subjects: 1793
Study 19892392 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional 18 months in the Oportunidades programme for children whose mothers had no education
Number of subjects: 1793
Study 16881772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medication management and intensive behavior therapy (Comb)
Number of subjects: 579
Study 16881772 — intervention group
Group type: COMPARATOR
Intervention: Medication management (MedMgt)
Number of subjects: 579
Study 16881772 — intervention group
Group type: COMPARATOR
Intervention: Community-treated comparison (CC)
Number of subjects: 579
Study 16881772 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavior therapy
Number of subjects: 579
Study 15701190 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked drain and ropivacaine
Number of subjects: 128
Study 15701190 — intervention group
Group type: EXPERIMENTAL
Intervention: Patent drain and ropivacaine
Number of subjects: 128
Study 15701190 — intervention group
Group type: COMPARATOR
Intervention: Blocked drain and saline
Number of subjects: 128
Study 15701190 — intervention group
Group type: COMPARATOR
Intervention: Patent drain and saline
Number of subjects: 128
Study 11339912 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphism of interleukin‐1 receptor antagonist gene
Number of subjects: 116
Study 11339912 — intervention group
Group type: EXPERIMENTAL
Intervention: Three mutant alleles of interleukin‐1 beta and interleukin‐1 receptor antagonist genes
Number of subjects: 116
Study 9198829 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxin treatment (started on average 5 years after surgery)
Number of subjects: 228
Study 9198829 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxin treatment (permanently treated)
Number of subjects: 228
Study 9198829 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with thyroxin, average 2 years after surgery)
Number of subjects: 228
Study 9198829 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxin treatment (in patients with nodular regrowth)
Number of subjects: 228
Study 9198829 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxin treatment (in patients with high serum TSH concentrations)
Number of subjects: 228
Study 1586270 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol low dose (2 to 13 ng/mL)
Number of subjects: 176
Study 1586270 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol medium dose (13.1 to 24 ng/mL)
Number of subjects: 176
Study 1586270 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol high dose (24.1 to 35 ng/mL)
Number of subjects: 176
Study 1586270 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single-blind period)
Number of subjects: 176
Study 3894872 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine solution (5 mg X kg‐1 body weight)
Number of subjects: 10
Study 3894872 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 3894872 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolyte‐glucose solution (ERG)
Number of subjects: 10